---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-033455"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:54:07.828333+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences reports FY 2023 net loss $69.1M; $403.5M cash after $200M PIPE

## Summary
- Q4 2023 net loss $22.8M vs $12.9M; FY net loss $69.1M vs $55.3M.
- Closed $200M PIPE in Feb 2024; pro-forma cash $403.5M to fund operations through at least 2026.
- TYRA-300 Phase 1 SURF301 initial data expected 2H 2024; Phase 2 IND for achondroplasia on track for 2H 2024.
- FDA granted Rare Pediatric Disease Designation for TYRA-300 in achondroplasia (Jan 2024).
- Initiated SURF201 Phase 1 study for TYRA-200 in FGFR2-altered cholangiocarcinoma.

## SEC filing metadata
- accession: 0000950170-24-033455
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000095017024033455/0000950170-24-033455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000095017024033455/tyra-20240319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-033455
- JSON: https://secwatch.observer/filing/0000950170-24-033455.json
- Plain text: https://secwatch.observer/filing/0000950170-24-033455.txt

## Key facts
- Earnings Releases
  Tyra Biosciences, Inc. reported the fiscal year ended December 31, 2023 results: net income Full year 2023 net loss was $69.1 million.
  - Period: the fiscal year ended December 31, 2023
  - Net income: Full year 2023 net loss was $69.1 million
  - Result: reported results
  source text: Full year 2023 net loss was $69.1 million compared to $55.3 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1863127/000095017024033455/0000950170-24-033455-index.htm
- Earnings Releases
  Tyra Biosciences, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net loss was $22.8 million.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Net income: net loss was $22.8 million
  - Result: reported results
  source text: Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1863127/000095017024033455/0000950170-24-033455-index.htm
- Earnings Releases
  Tyra Biosciences, Inc. reported the fourth quarter ended December 31, 2023 results: net income Fourth quarter 2023 net loss was $22.8 million.
  - Period: the fourth quarter ended December 31, 2023
  - Net income: Fourth quarter 2023 net loss was $22.8 million
  - Result: reported results
  source text: Fourth quarter 2023 net loss was $22.8 million compared to $12.9 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1863127/000095017024033455/0000950170-24-033455-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.